WallStSmart

Abbott Laboratories (ABT)vsCognizant Technology Solutions Corp Class A (CTSH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 110% more annual revenue ($44.33B vs $21.11B). ABT leads profitability with a 14.7% profit margin vs 10.6%. CTSH appears more attractively valued with a PEG of 1.02. CTSH earns a higher WallStSmart Score of 71/100 (B).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

CTSH

Strong Buy

71

out of 100

Grade: B

Growth: 5.3Profit: 7.5Value: 10.0Quality: 5.5
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued
CTSHUndervalued (+63.1%)

Margin of Safety

+63.1%

Fair Value

$192.25

Current Price

$59.79

$132.46 discount

UndervaluedFair: $192.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

CTSH3 strengths · Avg: 8.0/10
P/E RatioValuation
13.1x8/10

Attractively priced relative to earnings

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

EPS GrowthGrowth
22.1%8/10

Earnings expanding 22.1% YoY

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

CTSH2 concerns · Avg: 3.5/10
Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : CTSH

The strongest argument for CTSH centers on P/E Ratio, Price/Book, EPS Growth. PEG of 1.02 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : CTSH

The primary concerns for CTSH are Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

CTSH carries more volatility with a beta of 0.98 — expect wider price swings.

CTSH is growing revenue faster at 4.9% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CTSH scores higher overall (71/100 vs 51/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Cognizant Technology Solutions Corp Class A

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA

Cognizant is an American multinational technology company that provides business consulting, information technology and outsourcing services. It is headquartered in Teaneck, New Jersey, United States.

Want to dig deeper into these stocks?